distance connections [11] . However, the ability of proliferating NPCs to replace lost neurons is limited, since only few precursors differentiate into neurons, and most of the new neurons die shortly after generation [9, 12] . These recent findings underscore the need for a better understanding of injury-induced neurogenesis and suggest that manipulation of endogenous NPCs may become a potential strategy to promote brain reparative processes. To date, most studies in this field have examined mechanisms underlying NPC proliferation and neuronal differentiation after injury, whereas factors regulating enhanced migratory capacity and recruitment of neuroblasts to the site of brain damage are less well elucidated.
In the normal adult brain, the factors underlying migration of NPCs from the SVZ along the rostral migratory stream (RMS) are becoming evident. This long-distance migration involves regulation of various cellular processes, including cell adhesion, competency to migrate and ability to respond to directional signals. Directional cues are provided by a variety of chemorepulsive and chemoattractive factors arising from the lateral ventricle and brain parenchyma, or from the olfactory bulb and RMS astrocytes, respectively [for recent reviews, see 13, 14 ] . After brain injury, some mechanisms of NPC migration are similar to those occurring under physiological conditions, particularly in regard to signaling pathways that regulate cytoskeletal machinery to produce migration [14] ; however, it is apparent that additional injury-induced factors are necessary to enable neuroblasts to exit the SVZ/RMS and redirect their migration towards remote damaged regions. Amongst the myriad of molecules released in damaged brain tissue, some candidates potentially regulating the migration of NPCs and their neuroblast progeny consist of specific immune mediators upregulated during the inflammatory response elicited after injury, as well as growth factors. In this review, we provide an overview of an array of chemotactic cytokines, or chemokines, and growth factors that are released following ischemic and traumatic brain injuries and their capacity to stimulate the ectopic migration of SVZ NPCs.
Capacity for Redirected Migration of NPCs following Brain Injury

Focal Ischemia
Injury-induced neurogenesis has been most thoroughly investigated to date in models of focal cerebral ischemia, and the mechanisms of stimulated proliferation, migration, neuronal differentiation and survival are beginning to be elucidated [for recent reviews, see 5, 6, 15 ] . Focal ischemia occurs when blood flow to a specific brain region is interrupted, resulting in a discrete area of necrotic brain tissue surrounded by a hypoperfused penumbral region where at later stages vulnerable neural cells die. The most common experimental model of focal cerebral ischemia is transient middle cerebral artery occlusion (MCAO), which induces extensive damage to the striatum and cortex. Following MCAO, an early dramatic increase in SVZ precursor proliferation was demonstrated that persisted for at least 4 months [9, 12, 16] . This stimulated proliferation was matched by redirected migration of vast numbers of neuroblasts from the SVZ to the injured striatum [9, 12, [17] [18] [19] . The origin of NPCs migrating to the striatum after MCAO was identified by labeling SVZ cells prior to injury with lipophilic dye [17] or with transgenic expression of green fluorescent protein [19] , and both studies confirmed that following ischemia labeled SVZ cells migrated to the adjacent lesioned striatum. Yamashita et al. [19] further demonstrated that SVZ-derived neuroblasts differentiated into mature neurons and formed synaptic connections in the striatum, apparently contributing to brain repair. This redirected migration of NPCs from the SVZ to the site of injury can occur via multiple routes, including along blood vessels or astrocyte chains [16, 19, 20] , although the molecules responsible for this guidance are not yet fully elucidated.
Traumatic Brain Injury
Abundant recent studies have begun to characterize the neurogenic response following experimental models of traumatic brain injury (TBI). These studies have mostly utilized the lateral fluid percussion injury (FPI) and controlled cortical impact (CCI) modes of focal TBI in rats and mice. Lateral FPI is a form of focal injury that induces a unilateral cortical lesion and also includes a robust diffuse axonal injury component, and is produced by a global displacement of the brain by a fluid pulse [for a review, see 21 ] . Conversely, CCI is produced by a controlled, focal deformation of the brain by a metal piston and results in localized cell death and an extensive contusion cavity. In addition, a few very recent studies have also examined neurogenesis in a closed head injury weight drop model that causes a unilateral skull fracture with an underlying cortical contusion [21] . Following CCI, increased cellular proliferation was reported in the hippocampus and cortex, with new cells distributed around the lesion up to 60 days after injury [9, [22] [23] [24] [25] . These prolif-erating cells subsequently colocalized predominantly with markers of immature and mature neurons in the hippocampus, but in the pericontusional cortex, most new cells were identified as astrocytes and oligodendrocytes [9, 23, 26] . Similar to the CCI model, following lateral FPI, a significant increase in cell proliferation was seen in both the hippocampus and the SVZ within the first week after injury, with the majority of these cells colocalizing with markers of astrocytes and microglia [27] [28] [29] . Cellular proliferation was shown to persist for 1 year after FPI with many of these cells acquiring astrocytic or immature neuronal phenotypes [30] . In the closed head injury model, a similar enhancement in hippocampal and SVZ proliferation was described within the first week after trauma, with the new cells surviving in the cortex for up to 90 days acquiring a glial phenotype [ 31 ; Bye et al., unpubl. data] .
In comparison to the studies mentioned on experimental ischemia, the migration of NPCs from the SVZ to regions of tissue damage is less well characterized following traumatic injury, and little is known about the regulatory mechanisms involved. A few studies have definitively shown that SVZ NPCs migrate to the pericontusional cortex: following either retroviral labeling or incorporation of fluorescent microspheres or dye, large numbers of SVZ cells were identified within the pericontusional cortex from 3 days to 3 weeks following injury [24, 26, 32] . At earlier time points, some of the SVZ cells were colabeled with doublecortin (DCX; a microtubuleassociated protein expressed by NPCs and immature neurons), suggesting that at least a proportion of the cells were migrating neuroblasts, while at later times the majority of cells expressed glial markers. More recently, numerous studies have shown the presence of DCX-labeled neuroblasts in the pericontusional cortex from 1 to 90 days after TBI, which are proposed to have migrated from the SVZ [ 31, 33, 34 ; Bye et al., unpubl. data] . These reports clearly demonstrate the ongoing nature of this process, which is robust initially but diminishes over time. Furthermore, Itoh et al. [33] reported that a proportion of the DCX-labeled cells coexpressed the mature neuronal marker NeuN at 30 days, confirming that some neuroblasts may indeed survive to generate new neurons in the pericontusional cortex. Interestingly, some data suggest that neurogenesis after experimental trauma is associated with angiogenesis [31, 34] ; however, evidence of neuroblasts using new blood vessels as migratory guides, as seen after ischemic damage, remains to be explored following TBI.
Injury-Induced Factors Mediating Redirected Migration to Damaged Brain Regions
The pathophysiology of brain injury after ischemic or traumatic insults is complex, and although distinct, both injury types elicit a similar neuroinflammatory response. This multifaceted reaction comprises both cellular and molecular pathways involving directly the brain parenchyma and indirectly the contribution of peripheral immune cells. As a result of injury, the disruption of the blood-brain barrier permits the transmigration of leukocytes, including neutrophils and macrophages, from the systemic circulation, coincident with the activation of resident glial cells, the astrocytes and microglia. Both infiltrating peripheral immune cells and activated glia engage in the synthesis and release of numerous pro-and anti-inflammatory cytokines, chemokines, neurotransmitters and reactive oxygen and nitrogen species. These factors further disrupt the blood-brain barrier, sustaining the recruitment and activation of leukocytes and glia, thus creating a positive feedback loop which prolongs inflammation and contributes to ongoing neuronal damage [35] [36] [37] . It is becoming increasingly clear that amongst the plethora of factors released by activated glia, many are involved in regulating the neurogenic response after injury by mediating different neurogenic stages, including proliferation, neuronal differentiation and survival [for recent reviews, see [38] [39] [40] . More specifically, a number of chemokines and growth factors have recently been identified as necessary signals to stimulate the migration of SVZ NPCs and recruit neuroblasts to the damaged region; such factors are the focus of this review and will be discussed in detail below.
Activated Microglia and Reactive Astrocytes Regulate Neurogenesis after Injury
As part of the brain's innate inflammatory response to brain injury, microglia are rapidly activated and recruited to the damaged site, where they release numerous proand anti-inflammatory cytokines, chemokines and reactive nitrogen and oxygen species, but also a significant number of growth factors [41] . Early work investigating the contribution of activated microglia to injury-induced neurogenesis found a primarily deleterious role for these cells, in that inhibition of microglial activation by antiinflammatory treatment with minocycline and indomethacin resulted in enhanced hippocampal neurogenesis in models of cranial irradiation, epilepsy and ischemic stroke [42] [43] [44] [45] . Interestingly, such pharmacological approaches were associated with improved functional outcome [44] . However, recent studies have begun to reveal rather a dual role of activated microglia, which display a complex, multifaceted impact on injury-induced neurogenesis with both supportive and detrimental actions. While microglia-derived factors may stimulate the early stages of neurogenesis, their ultimate consequence may be to create an environment that is detrimental to the long-term survival of new neurons. Moreover, specific effects on neurogenesis may be dependent upon the degree of microglial activation, with robustly activated microglia being inhibitory, and more mildly activated microglia being supportive, and these diverse characteristics may be linked to the soluble factors that are selectively released [for reviews, see [38] [39] [40] . For example, the proinflammatory cytokines expressed by acutely activated microglia following lipopolysaccharide or interleukin (IL)-6 stimulation or during status epilepticus, including IL-1 ␤ , IL-6, IL-18, ␥ -interferon and tumor necrosis factor (TNF) ␣ , have been shown to specifically inhibit precursor proliferation, neuronal differentiation or survival of new neurons [42, [46] [47] [48] [49] . Conversely, microglia activated via an adaptive immunity response to low levels of the cytokine ␥ -interferon can instruct neuronal differentiation and survival [50] . In addition to cytokines, activated microglia in the injured brain also produce multiple chemokines, including CXCL12 and CCL2, and growth factors, such as brain-derived neurotrophic factor (BDNF) and epidermal growth factor (EGF) [41] , which in turn have been shown to promote multiple neurogenic stages, including precursor proliferation, neuronal differentiation and survival, as well as the redirected migration of neuroblasts to the damaged brain region [51] [52] [53] [54] .
In addition to microglia, astrocytes are pivotal in regulating injury-induced neuroinflammation [for reviews, see 55, 56 ] . In a rapid response to injury, astrocytes undergo reactive astrogliosis, involving cell proliferation, hypertrophy and increased expression of glial fibrillary acidic protein [56] . Similar to activated microglia, reactive astrocytes release a wide variety of cytokines, such as TNF ␣ , IL-1 ␤ , IL-6 and IL-10, as well as growth factors, such as BDNF, basic fibroblast growth factor (FGF2) and vascular endothelial growth factor (VEGF) [56] , which can have both negative and positive effects on neurogenesis. Thus, astrocytes are also likely to be important in regulating injury-induced neurogenesis. In support of this concept, in vitro experiments have shown that astrocytes cocultured with adult rat NPCs stimulate their proliferation and neuronal differentiation [57] ; however, the specific ability of astrocytes to regulate NPC migration after injury remains unexplored.
Chemokines
Chemokines form a family of small (8-14 kDa), mainly basic, secreted molecules that are primarily known for regulating chemoattraction of immune cells to sites of inflammation and tissue damage. The family is divided into 4 groups based on the relative position of the first N-terminal cysteine, with multiple members called ligands (L) in each group (CCL, CXCL, CX3CL and CL) [58, 59] . They bind to and signal through heterotrimeric G-protein-coupled 7-transmembrane domain receptors (R) named after each respective ligand family: CCR, CXCR, CX3CR, CR.
While most research on chemokines has focused on systemic inflammatory diseases, numerous studies have also shown that chemokines play multiple roles within the nervous system. They have widespread nonimmunological effects in the central nervous system (CNS), including regulation of neural cell proliferation, migration, survival and synaptic transmission and can act in a paracrine or autocrine manner [58, 60] . Chemokines and their receptors are constitutively expressed during development of the CNS, and their expression persists in the adult brain restricted to specific regions. To date most work on chemokines in the CNS has focused on their impact on NPCs, and both embryonic and adult mouse NPCs express most chemokine receptors in culture [61, 62] and some chemokines [62] . Human embryonic NPCs have also been reported to express the chemokine receptors CCR3 and CXCR4 [63, 64] . The pattern of expression of chemokines and their receptors in NPCs coincides with the pattern identified in the normal adult mouse brain, where almost all chemokine receptors and most CXC chemokines have been detected in the olfactory bulb at the highest levels, with variable levels of receptor expression in the other neurogenic regions, the SVZ and hippocampus. On the other hand, nonneurogenic regions of the brain, such as the cortex, constitutively express very few of the chemokine receptors and at low levels [62] . The abundant expression in the olfactory bulb suggests that multiple chemokines and their receptors may play a role in regulating the migration of NPCs to and within the olfactory bulb under normal conditions.
Following neural injury or inflammatory disease, the production of many chemokines is induced or enhanced in the CNS, including CCL2, CCL3, CXCL1, CXCL5, CCL12 and CXCL10 [65] [66] [67] [68] [69] . Expression of other chemokines, including CCL19, CCL21 and CXCL13, is primarily found on infiltrating immune cells or endothelial cells rather than on CNS parenchymal cells [70] . As major mediators of cerebral inflammation, a primary role of chemokines is to attract leukocytes to the injured tissue.
However, as discussed below, they may also be important for the recruitment of NPCs to regions of damaged brain tissue after injury.
The Chemokine CXCL12 Most studies exploring the role of chemokines in the nervous system have centered on the macrophage-attracting chemokine CXCL12 (or stromal-derived factor 1 ␣ ), since it is the most widespread and highly expressed chemokine in the CNS. Not only is CXCL12 with its receptor CXCR4 expressed in neurogenic brain regions, it is also expressed in nonneurogenic regions, such as the cortex, indicating that this chemokine functions not only in NPC migration, but also in normal adult parenchymal physiology [62, [71] [72] [73] [74] [75] [76] . CXCL12 also has multiple roles in neural development. It modulates the proliferation of embryonic NPCs in an EGF/FGF2-dependent manner [77] but is better known for regulating precursor cell migration in various nervous system regions, such as the cerebellum [60, 78, 79] and neural crest [73, 80] , as well as in radial glial cells [81] .
CXCL12 has also been the most widely studied chemokine with respect to NPC migration in the adult brain. The CXCL12/CXCR4 ligand/receptor pair promotes NPC migration in vitro [64, [82] [83] [84] in a phosphoinositol-3-kinase-dependent manner [85] . Moreover, in vivo studies showed that CXCL12/CXCR4 regulates the migration of NPCs of the SVZ in adult rodent brain [86] , with further work suggesting that CXCR7, an alternate CXCL12 receptor, is also involved in this process [87] .
In the pathological adult brain, expression of CXCL12 is increased after ischemia [16, 52, [88] [89] [90] and TBI [91] , predominantly by reactive astrocytes, activated microglia and endothelial cells. Evidence suggests that CXCL12 contributes to the endogenous NPC response to damage by directing their migration to the site of injury [16, 52, 92, 93] . Similarly, CXCL12 also promoted the mobility [93] and directed migration [16, 52, 92, 93] of neuroblasts derived from human or rodent NPCs that were transplanted into ischemic brain.
The Chemokine CCL2 The chemokine system of CCL2 (or monocyte chemoattractant protein 1) and its receptor CCR2 plays a crucial role in mediating monocyte, macrophage and microglial migration into the CNS under neuroinflammatory conditions [for a review, see 59 ]. CCL2 is acutely increased within the first hours in rodent models of ischemic stroke [54, 94, 95] and TBI [96] [97] [98] , being predominantly produced by astrocytes, resident microglia and infiltrating macrophages, and to a lesser extent by endothelial cells and neurons.
CCL2 has recently been identified as an important chemotactic factor for NPCs, which express CCR2 [61, 67] . In vitro chemotaxis assays using NPCs isolated from the SVZ of postnatal and adult rodents have shown that NPCs migrate in response to CCL2 [54, 67, 84, 92, 99] . Similarly, implanted NPCs and resident SVZ neuroblasts were recruited toward sites of recombinant CCL2 infusion into the brain in vivo [54, 100] .
CCL2 appears to be an important inflammatory factor playing a role in neuroblast migration also in the pathological brain. When NPCs were transplanted into hippocampal brain slices cultured from CCL2 or CCR2 knockout mice, they failed to migrate towards an inflammatory stimulus [101] . In ischemic brain in vivo, CCL2-dependent migration of neuroblasts to sites of tissue damage was also demonstrated using CCL2-or CCR2-deficient mice [54] . Our group recently observed a similar effect of CCL2 on neuroblast migration following experimental TBI: using a mouse model in which CCL2 greatly increases in the injured cortical tissue [98] , we found that the number of DCX-positive cells migrating from the SVZ to the pericontusional cortex was reduced by approximately 40% in mice deficient for CCL2 compared to wild-type controls [Bye et al., unpubl . data], thus corroborating the important role of this chemokine in traumainduced migration of neuroblasts to the lesioned cortex.
Other Chemokines Although less intensely investigated, other chemokines have also been shown to affect NPC migration. It was demonstrated that CXCL16 regulates migration of a glial precursor cell line [102] and CXCL8 and CXCL13 mediated NPC migration across endothelial cells in culture [103] . Additionally, CXCL1 has been shown to be a potent chemoattractant for cultured NPCs [67, 104] , while CCL3 and CXCL1 promote NPC migration following striatal cell loss [67] . The mechanisms by which chemokines promote the migration of cell types that migrate collectively with cell-cell contact, such as NPCs, are beginning to be elucidated and seem to involve the stabilization of cell protrusions at the forward edge of the polarized cells, resulting in directional migration [105] .
Given that many other chemokines and their receptors are differentially expressed in distinct neurogenic regions of the CNS [62] , it is conceivable that individual chemokines exert region-specific effects. For example, in the normal adult mouse brain CXCL1 is highly expressed in the adult hippocampus but is found at lower levels in the SVZ and olfactory bulb, whereas CXCL5 is abundant in the olfactory bulb and SVZ but low in the hippocampus [62] . However, despite its low constitutive expression, CXCL1 is upregulated in cultured SVZ-derived NPCs after stimulation by TNF ␣ . Together, these data suggest that CXCL1 may have a physiological role in the hippocampus and an inflammation-related role in the other neurogenic regions. Whether or not other chemokines may regulate the migration of NPCs or have other nonmigratory functions remains to be determined.
Growth Factors
Growth factors are proteins that modulate cell proliferation, differentiation and survival. It is well established that many, such as the neurotrophins, are critical for the developing and adult nervous system, while more recently, others, including hematopoietic growth factors, have been found to also influence neurogenesis. A wide variety of growth factors are released after brain injury, with their production being attributed to activated microglia, reactive astrocytes, endothelial cells and neurons [for reviews, see 35, 106 ] . It has become increasingly apparent that growth factors are important in stimulating injuryinduced neurogenesis. In particular, a number have been recently implicated in mediating NPC migration in the damaged brain, including erythropoietin (EPO), VEGF, granulocyte colony-stimulating factor (G-CSF), BDNF, FGF2 and EGF, as discussed in detail below. Erythropoietin EPO is a major hematopoietic cytokine with multiple neuroprotective functions in neuropathology [107] . In the adult brain, EPO and its specific receptor EPOR are expressed by neurons, astrocytes and capillary endothelial cells [108] . EPOR also colocalizes with NPCs in the adult SVZ [109] , implying a possible role in neurogenesis. In fact, robust evidence suggests that EPO and EPOR modulate embryonic and adult neurogenesis, particularly by enhancing precursor cell proliferation and the subsequent production of neuronal-lineage restricted progenitors [109] [110] [111] . In addition, studies are beginning to identify a specific role for EPO/EPOR in NPC migration in normal adult brain. Infusion of rhEPO into the lateral ventricle of adult naive mice increased the migration of SVZ progenitors towards the olfactory bulb, leading to a net gain in new interneurons, while administration of an anti-EPO neutralizing antibody significantly decreased the number of newly generated migrating cells, demonstrating that both exogenous and endogenous EPO can regulate neuroblast migration [109] .
The expression of EPO and EPOR in the brain increased in response to injury in patients [112, 113] as well as in models of ischemia [114] and TBI [115] , suggesting that endogenous EPO may contribute to injury-induced repair. In fact, using conditional EpoR knockdown mice, Tsai et al. [111] showed that brain-specific deletion of EpoR leads to a decrease in poststroke neurogenesis, in part due to impaired migration of neuroblasts to the periinfarct cortex. In addition, treatment with rhEPO enhanced injury-induced neurogenesis after experimental stroke and TBI by stimulating the migration of SVZ precursors to the peri-infarct/contusional region [116] [117] [118] [119] . The beneficial effects of rhEPO on postischemic progenitor migration are potentially mediated via matrix metalloproteinase 2 and 9 secretion via the phosphoinositol-3-kinase/Akt1 and ERK1/2 signaling pathways [120] .
Vascular Endothelial Growth Factor
Another pivotal hematopoietic growth factor with recently discovered roles in neurogenesis is VEGF. VEGF is a major angiogenic mediator that promotes proliferation and survival of endothelial cells [121] . It also acts as a guidance cue for endothelial progenitors and hematopoietic cells [122, 123] . Recently, neurotrophic and neuroprotective properties of VEGF have been identified in the CNS [124, 125] , with the VEGFR2 receptor (KDR/Flk1) apparently mediating most neuron-specific effects [126, 127] . The expression of VEGFR1 (Flt1) and VEGFR2 (KDR/Flk1) receptors has been identified on SVZ progenitors isolated from neonatal rat brain and cultured in the presence of FGF2 [128] . In the adult rodent brain, VEGF has been shown to mediate the neurogenic effects stimulated by exercise and an enriched environment on production of new hippocampal neurons [129] . In addition, intraventricular infusion of VEGF led to increased cell proliferation in the SVZ [130, 131] . Abundant evidence also supports the ability of VEGF to instruct the migration of SVZ neuroblasts, with mice lacking VEGF showing significant impairment in SVZ neurogenesis with fewer cells reaching the olfactory bulb [131] . Additionally, the release of VEGF from astrocytes induced proliferation and migration of SVZ neuroblasts towards the olfactory bulb in vivo, via stimulation of VEGFR1 [132] . In vitro studies using chemotaxis assays have further demonstrated that VEGF is an attractive guidance cue for the migration of undifferentiated NPCs isolated from neonatal rat SVZ [128] and cortex [133] , and that this effect is mediated via VEGFR2 but not VEGFR1 [128] .
VEGF is expressed in the CNS after experimental trauma and stroke [134] [135] [136] and has important implications in mediating ectopic migration of SVZ neuroblasts to the site of injury. Wang et al. [137] showed that VEGFoverexpressing mice had enhanced SVZ cell proliferation after permanent focal cerebral ischemia, with chains of migratory neuroblasts extending from the SVZ to the peri-infarct cortex, leading to an ultimate increase in the number of newly generated cortical neurons at 14-28 days. While not specifically examining the migration of new neuroblasts, others similarly showed that VEGF overexpression enhanced striatal neurogenesis in adult rat brain after MCAO [138, 139] , while infusion of VEGF into the lateral ventricle increased neurogenesis in the pericontusional cortex after focal TBI [31] .
Granulocyte Colony-Stimulating Factor The hematopoietic growth factor G-CSF has a welldefined role in stimulating the proliferation and differentiation of hematopoietic progenitor cells into neutrophils and modulating neutrophil actions and distribution in the body [140] . More recently, neuroprotective properties of endogenous and applied G-CSF have been established, and growing evidence suggests that G-CSF may also drive neurogenesis, with a role in survival, differentiation and migration of neural progenitor cells [141] . G-CSF and its receptor are widely expressed by neurons throughout the adult rat and human brain, and also by cells within the neurogenic regions of the SVZ and hippocampus [142, 143] . Consistently, G-CSF receptor was also found expressed in cultured adult human and rat SVZ and hippocampal NPCs [142, 143] , supporting a role for this ligand/receptor system in adult neurogenesis. When G-CSF was administered by peripheral infusion in rats subjected to MCAO, the recruitment of neuroblasts into the ischemic area of the neocortex was significantly enhanced, and the number of newly generated neurons in the dentate gyrus was also increased [143] . Similarly, G-CSF treatment increased the number of neuroblasts in the SVZ ipsilateral to the site of focal TBI [144] . G-CSF also promoted neuronal differentiation of adult NPCs isolated from rat SVZ and hippocampus [143] . Interestingly, G-CSF expression is dramatically upregulated in damaged tissue by approximately 100-fold after both experimental stroke [143] and TBI [145] , suggesting that endogenous G-CSF may be critical for injury-induced neuronal differentiation of newly divided NPCs, as well as the recruitment of neuroblasts to the injury site.
Brain-Derived Neurotrophic Factor BDNF is a prominent neurotrophin with an important role in regulating constitutive adult neurogenesis in both the hippocampus and SVZ. BDNF exists in two forms (pro-BDNF and mature BDNF) and mediates its diverse actions through two structurally distinct receptors: the p75 neurotrophin receptor (NTR), a member of the TNF receptor superfamily that binds all neurotrophins with a preference for pro-rather than mature BDNF, and its specific high-affinity receptor TrkB, a member of the Trk family of receptor tyrosine kinases [146] . To date, the ability of pro-BDNF to regulate adult neurogenesis is relatively unknown, with most studies assessing effects of the mature form.
Evidence exists for a role of BDNF in regulating neuronal commitment of NPCs of both the hippocampus and the SVZ. For example, cell culture studies have shown that BDNF is essential for the differentiation of hippocampal progenitors into neurons [147] . This effect may be mediated by p75NTR, which is expressed in cells of the dentate gyrus [148] and was shown to regulate neuronal commitment and survival of hippocampal precursors [149] . Consistently, mice lacking BDNF have reduced hippocampal neurogenesis due to hindered granule cell differentiation [150] . In the adult SVZ, a population of highly proliferative precursors expresses p75NTR and responds similarly to BDNF by committing to a neuronal fate [151] . Interestingly, p75NTR expression is decreased while TrkB expression is increased on immature dentate gyrus neuroblasts, with TrkB levels continue to increase as the cells reach maturity [152, 153] . Studies using mice with TrkB deletion specifically from adult precursors demonstrated that TrkB is necessary for terminal differentiation and integration of new neurons into hippocampal circuits [154] .
Besides neuronal differentiation, BDNF is also important for regulating SVZ NPC migration through the RMS to the olfactory bulb [for a recent review, see 155 ] . In mice genetically altered to lack the regulated secretion of BDNF, neuroblast migration was reduced and fewer new olfactory bulb neurons were evident, with no effect on NPC proliferation in the SVZ [156] . Consistently, infusion of BDNF into the lateral ventricles or viral overexpression in the anterior SVZ resulted in enhanced neuronal migration to the olfactory bulb and also into the adjacent striatum, while increasing the survival of new neurons [53, [157] [158] [159] [160] . Interestingly, in vitro assays revealed that BDNF can both enhance motility of NPCs as well as act as a chemoattractant [161] . TrkB likely mediates the effects of BDNF on neuroblast migration, since it is specifically localized to migrating neuroblasts within the SVZ, RMS and subependymal layer of the olfactory bulb [156, 161, 162] . This is consistent with studies using explant culture assays showing that BDNF induced the migration of neuroblasts derived from early postnatal tissue, and that this effect was lost when TrkB was inhibited [161] . At present, there are disagreements in the literature in regard to whether p75NTR is also expressed by migratory neuroblasts in the RMS [155] , and therefore ongoing work is necessary to clarify its potential contribution to BDNF-mediated neuroblast migration.
It can be hypothesized that endogenous BDNF is involved in injury-induced neurogenesis. Many studies of experimental stroke and TBI have shown that BDNF mRNA and protein expression is increased from hours to weeks after injury in the damaged tissue, as well as in remote regions including the hippocampus [163] [164] [165] [166] [167] [168] . However, only a few studies have investigated the role of BDNF on neurogenesis following brain insults. In a quinolinic acid lesion model, BDNF overexpression enhanced the recruitment of NPCs to the lesioned striatum and promoted their neuronal differentiation and survival [159] . Similarly, in ischemia, intravenous BDNF stimulated NPC migration to the striatum, which coincided with improved neurological recovery [169] .
Basic Fibroblast Growth Factor FGF2 is a member of the FGF family displaying trophic effects in the brain during development [170] and having a major role in CNS injury responses [171] . FGF2 is widely distributed throughout the brain and is expressed by astrocytes, endothelium and some neuronal populations [172] . FGF2 signals predominantly through tyrosine kinase FGF receptor 1 (FGFR1), via complex intracrine and autocrine modes of action [173] . FGF2 is an essential mitogen for NPCs in vitro [174] [175] [176] [177] , while in vivo, the administration of FGF2 results in an increase in proliferation and neuronal differentiation in the SVZ, olfactory bulb and dentate gyrus [178] [179] [180] .
FGF2 and FGFR1 are upregulated in several forms of adult brain injury, including trauma [181] [182] [183] and ischemia [184, 185] , and both have been localized predominantly to reactive astrocytes around the lesioned tissue [182, 183] . Evidence suggests that FGF2 and FGFR1 are both required for neurogenesis after cortical damage [186, 187] , and a number of studies have shown that treatment with FGF2 enhances neurogenesis after brain injury by stimulating NPC proliferation and neuronal differentiation [188] [189] [190] [191] . Relatively few studies have investigated the potential of FGF2 for mediating the migration of NPCs in pathological brain. In a chemotaxis assay using NPCs from neonatal rat SVZ, VEGF induced directional migration of NPCs via VEGFR2 signaling, and interestingly, this chemotactic response was dependent upon the presence of FGF2, which increased VEGFR2 expression [128] . Similarly, cultured adult NPCs transplanted into the olfactory bulbs of postnatal mice were able to undergo significant migration from the site of injection and subsequent neuronal maturation, only when the NPCs were exposed to FGF2 prior to grafting [192] . Finally, when NPCs overexpressing FGF2 were transplanted into neonatal ischemic cortex, they had increased proliferative activity and showed dramatically enhanced migration into the site of brain injury compared to nonoverexpressing NPC controls [193] . This effect was apparently mediated via an autocrine signaling loop, since FGF2-overexpressing NPCs did not affect the migratory behavior of coimplanted nonoverexpressing NPCs. Altogether, these data suggest that FGF2 may be important for enabling NPCs to respond to chemoattractant cues secreted at the site of injury.
Epidermal Growth Factor EGF is important for the regulation of proliferation, differentiation, migration and survival of multiple cell types throughout the body. In the adult CNS, EGF receptor (EGFR) is highly expressed on stem cells and transitamplifying progenitor cells in the SVZ, and is also present at low levels on a subpopulation of SVZ neuroblasts [194] [195] [196] . It is well established that EGF and EGFR signaling regulates the proliferation of adult NPCs in the SVZ. For example, infusion of EGF into the lateral ventricle increased proliferation of adult SVZ NPCs in vivo [51, 179] , and EGF is also necessary for the in vitro formation of neurospheres [174, 197] . Accordingly, in mice null for the EGFR agonist transforming growth factor (TGF) ␣ , a dramatic reduction of NPC proliferation was shown in the SVZ [198] . EGF may also stimulate migration of NPCs, since infusion of EGF into the lateral ventricle caused not only a striking increase in NPC proliferation, but also in their migration away from the lateral ventricle walls into adjacent normal brain parenchyma [51, 195, 199] . In support of a role in migration, application of EGF to neurospheres derived from adult mouse SVZ NPCs resulted in a rapid reorganization of the cytoskeleton and significant changes in cell structure typical of a migratory phenotype, which was accompanied by enhanced cell migration [200] . Furthermore, overexpression of EGFR confers migratory properties on SVZ precursors in vitro and in vivo [201] . However, Kim et al. [196] found that EGFR was only expressed at low levels on a small subpopulation of SVZ neuroblasts in adult mouse slice preparations, and exposure to TGF ␣ significantly decreased the percentage of migrating cells. Altogether, these data demonstrate that further work is required to distinguish the role of EGF between the proliferation and migration of SVZ precursors.
Experimental evidence does suggest that EGF could potentially stimulate the migration of NPCs from the SVZ to adjacent brain regions in pathological contexts. EGF was increased in the injured region of the cortex to which SVZ cells migrated after cortical aspiration [202] , while cerebral ischemia produced a larger number of EGFR-positive NPCs in the SVZ [20, 203] . Following nigrostriatal denervation, TGF ␣ infusion into the striatum induced emigration of SVZ cells [204, 205] , while reduction of EGFR signaling in progenitors expressing neuron glial antigen 2 decreased their proliferative and migratory response to demyelination [206] . Interestingly, Ninomiya et al. [203] showed that in the ischemic brain there was an increase in the number of NPCs but a decrease in neuroblasts during EGF infusion into the parenchyma; however, 6 days after the discontinuation of EGF delivery, there was a substantial rise in the number of neuroblasts in the SVZ and striatum. In a separate study, EGF infusion similarly increased the number of NPCs, which subsequently led to enhanced migration of neuroblasts into the ischemic striatum and the ultimate production of new striatal interneurons [20] . In the same study, migrating neuroblasts were associated with a network of cells positive for glial fibrillary acidic protein with elongated processes linking the SVZ to the striatal lesion, which was only present in the EGF-treated brains [20] . Similarly, in a rat explant culture model of cerebellar development, granule cell migration was enhanced following EGF exposure in association with elongation of glial processes [207] . Altogether, these results suggest that enhanced migration of SVZ cells into the striatum occurring after EGF infusion is likely indirect, resulting from an expanded progenitor cell population and amplified glial support.
Concluding Remarks
Activated microglia and reactive astrocytes play a major role in the neuroinflammatory response to ischemic injuries and TBI, releasing a plethora of pro-and antiinflammatory cytokines, chemokines and growth factors. While the role of such factors in mediating the inflammatory response and contributing to neuronal degeneration has been well established, more recently it has been recognized that in the injured brain these same factors also support regenerative processes, including neurogenesis. Specifically, enhanced motility of NPCs and directional cues imparted by chemokines and growth factors are necessary to recruit new neuroblasts from the SVZ/RMS towards the damaged tissue. While a number of factors involved in stimulating injury-induced migration have been identified, their distinct ability in modulating motility or direction remains unclear in most, but not all, instances. For example, FGF2 has been shown to enable NPCs to respond to chemoattractants, while VEGF and CXCL12 appear to predominantly provide directional signals. Interestingly, BDNF and CCL2 can affect both motility and direction of migration, and this may depend upon whether they are being released in the SVZ or at the site of tissue damage. However, more studies are necessary to identify the relative importance of individual factors and determine which are most effective in supporting NPC migration, whether alone or in combination. It is also important to consider the balance between stimulating neuroblast recruitment and inhibiting other neurogenic stages, such as neuronal differentiation and survival of new cells, since chemokines and growth factors are known to have multiple inhibitory actions on the different stages of neurogenesis. Altogether, such insights could ultimately enable the development of new therapeutic approaches for the treatment of brain injury.
